[go: up one dir, main page]

BR9713199A - Péletes de desintegração rápida - Google Patents

Péletes de desintegração rápida

Info

Publication number
BR9713199A
BR9713199A BR9713199-7A BR9713199A BR9713199A BR 9713199 A BR9713199 A BR 9713199A BR 9713199 A BR9713199 A BR 9713199A BR 9713199 A BR9713199 A BR 9713199A
Authority
BR
Brazil
Prior art keywords
pellets
contain
rapid disintegration
release rate
relates
Prior art date
Application number
BR9713199-7A
Other languages
English (en)
Inventor
Michaela Opitz
Hendrik Von Bueren
Rolf-Dieter Gabel
Geoffrey Lee
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7805374&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9713199(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of BR9713199A publication Critical patent/BR9713199A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/20—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by expressing the material, e.g. through sieves and fragmenting the extruded length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Patente de Invenção: <B>"PéLETES DE DESINTEGRAçãO RáPIDA"<D>. A invenção refere-se a formas farmacêuticas de administração que estão na forma de péletes, as quais contêm um agente de retardo, na qual a taxa de liberação da substância ativa não é retardada ou é substancialmente idêntica comparada ao péletes correspondentes que não contêm agente de retardo. A taxa de liberação desses péletes de desintegração rápida é pelo menos cerca de 90% dentro de um período de tempo de 30 minutos. Além disso, a presente invenção também refere-se a processos para a produção desses péletes.
BR9713199-7A 1996-09-12 1997-09-09 Péletes de desintegração rápida BR9713199A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19637082A DE19637082A1 (de) 1996-09-12 1996-09-12 Schnellzerfallende Pellets
PCT/EP1997/004897 WO1998010754A1 (de) 1996-09-12 1997-09-09 Schnellzerfallende pellets

Publications (1)

Publication Number Publication Date
BR9713199A true BR9713199A (pt) 2000-04-04

Family

ID=7805374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9713199-7A BR9713199A (pt) 1996-09-12 1997-09-09 Péletes de desintegração rápida

Country Status (18)

Country Link
US (2) US6224909B1 (pt)
EP (1) EP0925060B2 (pt)
JP (1) JP2001513752A (pt)
KR (1) KR100514467B1 (pt)
CN (1) CN1146409C (pt)
AR (1) AR012829A1 (pt)
AT (1) ATE228830T1 (pt)
AU (1) AU730673B2 (pt)
BR (1) BR9713199A (pt)
CA (1) CA2265766C (pt)
DE (2) DE19637082A1 (pt)
DK (1) DK0925060T3 (pt)
ES (1) ES2187822T5 (pt)
PT (1) PT925060E (pt)
TR (1) TR199901147T2 (pt)
TW (1) TW508250B (pt)
WO (1) WO1998010754A1 (pt)
ZA (1) ZA978171B (pt)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9814150A (pt) * 1997-11-12 2000-10-03 Dow Chemical Co Processo para produzir uma composição de pelìcula-revestimento de escoamento livre, sem poeira, dispersável em água fria, comestìvel, e composição de extrudado.
WO1999024017A1 (en) * 1997-11-12 1999-05-20 Boehringer Mannheim Pharmaceuticals Corporation - Smithkline Bechman Corporation Limited Partnership No.1 Novel oral dosage form for carvedilol
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
EP0968714A1 (de) * 1998-07-02 2000-01-05 Roche Diagnostics GmbH Verfahren zur Herstellung schnellauflösender pharmazeutischer Zubereitungen von schwerlöslichen Wirkstoffen
US6852337B2 (en) * 1998-04-09 2005-02-08 Roche Diagnostics Gmbh Carvedilol-galenics
DE69910188T2 (de) * 1998-04-09 2004-06-17 Roche Diagnostics Gmbh Arzneiformen enthaltend carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
EP1146856B1 (en) * 1999-01-12 2003-07-02 Merck Sharp &amp; Dohme Limited Spheronised self-emulsifying system for hydrophobic and water-sensitive agents
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
DE19930795A1 (de) * 1999-07-03 2001-01-11 Encapbiosystems Ag Schiers Verfahren zur Verkapselung von Substanzen sowie Teilchen dafür
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
ES2227206T3 (es) * 2000-04-03 2005-04-01 F. Hoffmann-La Roche Ag Soluciones concentradas de carvedilol.
US20010036959A1 (en) * 2000-04-03 2001-11-01 Gabel Rolf Dieter Carvedilol-hydrophilic solutions
AU5066101A (en) * 2000-04-13 2001-10-30 Synthon B.V. Modified release formulations containing a hypnotic agent
CA2426811A1 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
AU2256702A (en) 2000-12-01 2002-06-11 Kyowa Hakko Kogyo Kk Composition improved in solubility or oral absorbability
EP1275377B1 (en) * 2001-07-11 2003-06-18 Apr Applied Pharma Research S.A. Granulates containing liposoluble substances and process of preparation thereof
AR034813A1 (es) * 2001-07-20 2004-03-17 Novartis Ag Composiciones farmaceuticas y uso de las mismas
AU2002341901A1 (en) * 2001-10-01 2003-04-14 Smithkline Beecham Corporation Novel compositions of carvedilol
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
BR0307516A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formas de dosagem de liberação imediata contendo dispersões de uma droga sólida
US6958161B2 (en) * 2002-04-12 2005-10-25 F H Faulding & Co Limited Modified release coated drug preparation
US9107804B2 (en) * 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
JP2006518380A (ja) 2003-01-31 2006-08-10 スミスクライン・ビーチャム・コーポレイション 固体分散体組成物
US7182738B2 (en) * 2003-04-23 2007-02-27 Marctec, Llc Patient monitoring apparatus and method for orthosis and other devices
US7829595B2 (en) 2003-09-12 2010-11-09 Amgen Inc. Rapid dissolution formulation of a calcium receptor-active compound
WO2005051322A2 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Controlled release pharmaceutical formulations comprising carvedilol, free based and its salts
US20050169994A1 (en) * 2003-11-25 2005-08-04 Burke Matthew D. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
EP1696888B1 (en) * 2003-12-23 2015-04-08 Temrel Limited Process for producing pellets for pharmaceutical compositions
GB0329851D0 (en) * 2003-12-23 2004-01-28 Temrel Inc Process for producing particles for pharmaceutical compositions
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
WO2005123042A1 (en) * 2004-06-10 2005-12-29 Glatt Air Techniques, Inc. Controlled release pharmaceutical formulation
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
WO2006036964A2 (en) 2004-09-28 2006-04-06 Atrium Medical Corporation Barrier layer
DE102005004893B4 (de) * 2005-02-03 2011-02-10 Dow Global Technologies Inc., Midland Verfahren zur Formgebung von Celluloseethern
WO2006085497A1 (ja) * 2005-02-09 2006-08-17 Kissei Pharmaceutical Co., Ltd. 口腔内崩壊錠
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US7811604B1 (en) 2005-11-14 2010-10-12 Barr Laboratories, Inc. Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
WO2007071420A1 (en) * 2005-12-23 2007-06-28 Lek Pharmaceuticals D.D. Bursting pellets
EP2010162A4 (en) * 2006-04-03 2013-01-09 Isa Odidi COMPOSITION FOR DISPOSING A MEDICINAL PRODUCT
EP2043613A1 (en) * 2006-07-14 2009-04-08 Fmc Corporation Solid form
WO2008070072A2 (en) * 2006-12-01 2008-06-12 Mutual Pharmaceutical Company, Inc. Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
WO2008130234A1 (en) * 2007-04-19 2008-10-30 Disphar International B.V. High dose composition of ursodeoxycholic acid
CA2719921A1 (en) * 2008-03-28 2009-10-01 Lintec Corporation Orally-administered agent
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
EP2540294B1 (en) * 2010-02-22 2016-08-03 Daiichi Sankyo Company, Limited Sustained-release solid preparation for oral use
WO2011102504A1 (ja) * 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
WO2011102505A1 (ja) * 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
AU2011224350B2 (en) * 2010-03-09 2015-07-02 Alkermes Pharma Ireland Limited Alcohol resistant enteric pharmaceutical compositions
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
EP2659882A4 (en) * 2010-12-27 2014-11-12 Tomita Pharma DISPOSABLE CORE PARTICLES FOR PHARMACEUTICAL FORMULATION
DE112011105038T5 (de) 2011-03-14 2013-12-12 Hewlett-Packard Development Co., L.P. Vorrichtung, System und Verfahren mit fortlaufender Tintenversorgung
JP2014529630A (ja) 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
KR102127625B1 (ko) 2012-09-03 2020-06-29 다이이찌 산쿄 가부시키가이샤 하이드로모르폰염산염 함유의 경구용 서방성 의약 조성물
KR102158339B1 (ko) * 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제
ES2902174T3 (es) 2016-07-19 2022-03-25 Exact Sciences Dev Co Llc ADN de control metilado
CN108421497A (zh) * 2018-04-03 2018-08-21 杨高品 药物连续化制粒的生产工艺和设备
TW202448511A (zh) * 2023-05-11 2024-12-16 英商康泰倫特英國斯文敦載迪斯有限公司 增加活性醫藥成分之胃前吸收的滲透性

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3532692A1 (de) 1985-09-13 1987-03-19 Boehringer Mannheim Gmbh Verfahren zum herstellen von tabletten aus pellets
US5258185A (en) * 1989-08-23 1993-11-02 Bauer Kurt H Highly active, rapidly absorbable formulations of glibenclamide, processes for the production thereof and their use
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
HU219341B (en) 1990-07-02 2001-03-28 Roche Diagnostics Gmbh Process for producing pressed, moulded, delayed release dose units and dose units thus produced
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
TW355683B (en) * 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
DE4413350A1 (de) 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
WO1996001623A1 (en) * 1994-07-08 1996-01-25 Astra Aktiebolag Multiple unit tableted dosage form i
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation

Also Published As

Publication number Publication date
EP0925060A1 (de) 1999-06-30
WO1998010754A1 (de) 1998-03-19
PT925060E (pt) 2003-04-30
DE19637082A1 (de) 1998-03-19
TR199901147T2 (xx) 1999-07-21
ES2187822T5 (es) 2010-10-28
EP0925060B1 (de) 2002-12-04
US20010004458A1 (en) 2001-06-21
AU730673B2 (en) 2001-03-08
TW508250B (en) 2002-11-01
EP0925060B2 (de) 2010-06-16
ES2187822T3 (es) 2003-06-16
CN1237104A (zh) 1999-12-01
CA2265766A1 (en) 1998-03-19
US6379706B2 (en) 2002-04-30
CA2265766C (en) 2006-04-25
AR012829A1 (es) 2000-11-22
AU4553997A (en) 1998-04-02
ZA978171B (en) 1999-03-11
ATE228830T1 (de) 2002-12-15
US6224909B1 (en) 2001-05-01
CN1146409C (zh) 2004-04-21
DK0925060T3 (da) 2003-04-07
DE59708898D1 (de) 2003-01-16
KR100514467B1 (ko) 2005-09-15
KR20000036013A (ko) 2000-06-26
JP2001513752A (ja) 2001-09-04

Similar Documents

Publication Publication Date Title
BR9713199A (pt) Péletes de desintegração rápida
HU9600599D0 (en) Active principles and gas containing microparticles
ES2174920T3 (es) Producto de combinacion para la contracepcion que contiene agentes antagonistas de progesterona y un agente gestageno.
BG102744A (bg) Дозирана лекарствена форма на ибупрофен
BR9611015A (pt) Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto
BR0215193A (pt) Formulações de azitromicina diretamente compressìveis
EA199900964A1 (ru) Соли сертралина и лекарственные формы с длительным высвобождением сертралина
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
KR970704429A (ko) 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases)
AR003908A1 (es) Tableta de liberacion controlada
BR9916829A (pt) Formulações aerossóis farmacêuticas contendo fluoroalcanos, budesonida e formoterol
BR9913945A (pt) Composição farmacêutica para o tratamento de distúrbios agudos por meio de administração sublingual, e, processo para o tratamento de distúrbios agudos
BR0012488A (pt) Composição farmacêutica, métodos para melhorar a taxa de absorção de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para melhorar o inìcio do benefìcio terapêutico de um ou mais do que um agente farmaceuticamente ativo em mamìferos, para inibição de gastroirritação em um mamìfero, e para tratamento de mamìferos necessitando do tratamento proporcionado por um ou mais do que um agente farmaceuticamente ativo, e, processo para preparar uma composição farmacêutica
ES2163236T3 (es) Preparacion de 1,1,1,3,3-pentafluoropropano.
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
ES2172592T3 (es) Agente antagonista de progesterona y agente gestageno para el tratamiento de la endometriosis y del liomioma uterino.
ES2189768T3 (es) Sintesis regioselectiva de derivados de rapamicina.
ES2196079T3 (es) Procedimiento de fabricacion de unidades posologicas por medio de una granulacion por via humeda.
BR0215175A (pt) Métodos para a granulação úmida de azitromicina
KR920021145A (ko) 뇌 글루타메이트의 과다방출의 억제에 유용한 제형
NZ500664A (en) Process for making flurbiprofen lozenges by granulating flubiprofen with a bulking agent (selected from calcium carbonate, tricalcium phosphate or microcrystalline cellulose)
HUP0000141A2 (hu) Eljárás legfeljebb 90 tömeg% gyógyhatású anyagot tartalmazó pelletek előállítására
EP0460062A4 (en) Method for the synthesis of huperzine a and analogs thereof and compounds useful therein
IT1265101B1 (it) Derivati dell&#39;acido 2-ammino-4-fenil-4-osso butirrico
WO1999061010A3 (en) Treatment of infertility with cam-increasing compounds alone or in combination with at least one meiosis-stimulating compound

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO REQUISITO DE ATIVIDADE INVENTIVA, DE ACORDO COM O ARTIGO 8O, COMBINADO COM O ARTIGO 13, DA LPI 9279, DE 14/05/1996

B12B Appeal against refusal [chapter 12.2 patent gazette]